Cerebrovascular reactivity assessed with functional near-infrared spectroscopy as a biomarker of traumatic microvascular injury after traumatic brain injury
Enrolling By Invitation
99 years or below
All
170 participants needed
1 Location
Brief description of study
Traumatic cerebrovascular injury (TCVI) is common after traumatic brain injury (TBI) and an attractive target for therapeutic intervention. We will longitudinally measure cerebrovascular reactivity (CVR) by functional near-infrared spectroscopy (fNIRS) in acute (3 days from injury), subacute, and chronic phases after TBI as a biomarker of TCVI as compared to healthy controls. CVR will be measured by fNIRS response to hypercapnia. We hypothesize that CVR will be decreased after TBI and that these decreases will correlate with clinical outcomes. Furthermore, we predict that administration of a vasodilatory medication (sildenafil) will augment CVR after TBI.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: TBI
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 825942
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
